These observations provide direct evidence that Polδ makes a substantial contribution to TLS in vivo and suggests that at least some of the mutagenesis in the absence of the proofreading activity of Polδ, as observed for instance in a subset of cancers, is the result of more proficient lesion bypass by the enzyme. The gene discussed is POLD1; the disease is cancer.